Roberta Zappasodi

18PUBLICATIONS
207CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Cancer geneticsMedical infection agents (incl. prions)Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Molecular targets
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (18)

|Nov 17, 2025
Thrombospondin-1-CD47 signaling contributes to the development of T cell exhaustion in cancer.

Chien-Huan Weng, Anais Assouvie, Lauren Dong

|Jul 25, 2025
First-in-Human Phase I/II Study of INCAGN01876, a Glucocorticoid-Induced Tumor Necrosis Factor Receptor Agonist, in Patients with Advanced or Metastatic Solid Tumors.

Omid Hamid, Dana B Cardin, F Stephen Hodi

|Apr 03, 2024
Loss of CREBBP and KMT2D cooperate to accelerate lymphomagenesis and shape the lymphoma immune microenvironment.

Jie Li, Christopher R Chin, Hsia-Yuan Ying

|Oct 27, 2023
APR-246 increases tumor antigenicity independent of p53.

Judith Michels, Divya Venkatesh, Cailian Liu

|Jun 26, 2023
Updates on radiotherapy-immunotherapy combinations: Proceedings of 6th annual ImmunoRad conference.

Fabiana Gregucci, Sheila Spada, Mary Helen Barcellos-Hoff

|Jun 15, 2022
Calreticulin mutant myeloproliferative neoplasms induce MHC-I skewing, which can be overcome by an optimized peptide cancer vaccine.

Mathieu Gigoux, Morten O Holmström, Roberta Zappasodi

Pageof 3